Trust Point Inc. Sells 1,165 Shares of Eli Lilly and Company (NYSE:LLY)

Trust Point Inc. decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 29.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,855 shares of the company's stock after selling 1,165 shares during the quarter. Trust Point Inc.'s holdings in Eli Lilly and Company were worth $2,358,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Cyndeo Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 8.8% in the first quarter. Cyndeo Wealth Partners LLC now owns 12,937 shares of the company's stock worth $10,685,000 after purchasing an additional 1,045 shares during the last quarter. Hanson & Doremus Investment Management boosted its position in Eli Lilly and Company by 17.7% during the first quarter. Hanson & Doremus Investment Management now owns 3,840 shares of the company's stock valued at $3,171,000 after acquiring an additional 578 shares during the last quarter. Stillwater Capital Advisors LLC boosted its position in Eli Lilly and Company by 18.9% during the first quarter. Stillwater Capital Advisors LLC now owns 1,301 shares of the company's stock valued at $1,075,000 after acquiring an additional 207 shares during the last quarter. CHB Investment Group LLC boosted its position in Eli Lilly and Company by 1.5% during the first quarter. CHB Investment Group LLC now owns 3,164 shares of the company's stock valued at $2,613,000 after acquiring an additional 48 shares during the last quarter. Finally, Access Financial Services Inc. bought a new stake in Eli Lilly and Company during the first quarter valued at $319,000. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 0.8%

NYSE:LLY opened at $818.56 on Monday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm has a market cap of $775.78 billion, a price-to-earnings ratio of 69.90, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The firm has a 50-day moving average price of $775.43 and a two-hundred day moving average price of $801.69.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company's quarterly revenue was up 45.2% on a year-over-year basis. During the same quarter last year, the business posted $2.58 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were paid a $1.50 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.73%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price target for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Guggenheim reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.